EDIT vs RCL · rev $32.3M vs P/E 26, rev $16.48B
Editas Medicine Inc (EDIT) versus Royal Caribbean Cruises Ltd (RCL) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Royal Caribbean Cruises Ltd (RCL) is a travel services company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported RCL revenue for 2024-12-31 was $16.48B. Net income was $2.90B. Revenue was up 18.6% from 2023-12-31 to 2024-12-31. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
EDIT currently screens at market cap $375.2M. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
Not investment advice. Open the EDIT and RCL stock pages for the full models.
Not investment advice.